Hemostatic changes after COVID-19 vaccination in patients with hematologic malignancy diseases
Recruiting
- Conditions
- Cancer patients are considered to be at higher risk of thrombosis than the normal population. As previously reported, thromboembolic complications are five times more common among cancer patients than the normal population, with up to 10-15% during the incurable period. Patients with hematologic malignancies also have an increased risk of thromboembolic complications.Hemostatic changes after COVID-19 vaccination in patients with hematologic malignancy diseases
- Registration Number
- TCTR20211109005
- Lead Sponsor
- Siriraj Hospital Mahidol University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
1.The patient 18 years and older and diagnosis leukemia and lymphoma under treatment or is undergoing follow-up
2.the patient receive the first dose of COVID-19 vaccinate not limited to the brand name and has not been infected with covid-19 before.
Exclusion Criteria
1 .Pregnant woman.
2. History of venous thromboembolism in the past 3 months.
3. History of receiving other vaccines within 28 days before vaccination against COVID-19.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of D-dimer values before and after vaccination against COVID-19 in all patients with leukemia and lymphoma. First visit and 3 weekly D-dimer values
- Secondary Outcome Measures
Name Time Method thrombin generation assay before and after vaccination against COVID-19 in all patients with leukemia and lymphoma. First visit and 3 weekly Thrombin generation assay values,Anti pf4 values before and after vaccination against COVID-19 in all patients with leukemia and lymphoma. First visit and 3 weekly Anti pf4 values